Skip to main content

Table 2 Immunoreactive Score of Drp1, phospho-Drp1Ser637, CaMKI, phospho-CaMKIThr177 of the tumor and CA125 in relation to clinical factors of patients with ovarian cancer

From: Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer

VariableNumber of patientsDrp1phospho-Drp1Ser637CaMKIphospho-CaMKIThr177CA125
mean ± SEpmean ± SEPmean ± SEpmean ± SEpmean ± SEp
Age
  < 552010.05 ± 0.520.0544.75 ± 0.660.0539.25 ± 0.550.2311.10 ± 0.240.311792.3 ± 376.30.127
  ≥552911.17 ± 0.35 6.45 ± 0.57 10.10 ± 0.44 0.86 ± 0.21 2141.0 ± 921.6 
FIGO stage
 I-II2210.14 ± 0.460.0505.00 ± 0.580.1338.77 ± 0.520.011*0.73 ± 0.190.122340.8 ± 195.6< 0.001*
 III-IV2711.19 ± 0.39 6.37 ± 0.63 10.56 ± 0.42 1.15 ± 0.24 2608.7 ± 987.8 
Histology
 High-grade serous carcinoma2111.24 ± 0.430.0986.62 ± 0.610.034*9.71 ± 0.520.9741.05 ± 0.260.5022832.5 ± 1243.60.003*
 Non- high-grade serous carcinoma2810.32 ± 0.42 5.11 ± 0.61 9.79 ± 0.48 0.89 ± 0.20 658.9 ± 278.7 
Completeness of surgical reduction
 Complete or optimal3910.39 ± 0.360.0855.15 ± 0.460.006*9.46 ± 0.400.1161.03 ± 0.190.6691753.4 ± 712.70.264
 Suboptimal1012.00 ± 0.00 8.10 ± 0.94 10.90 ± 0.57 0.70 ± 0.15 955.0 ± 281.5 
Treatment response
 Responders3210.34 ± 0.400.2095.00 ± 0.470.007*9.25 ± 0.440.2521.00 ± 0.230.7321118 ± 381.50.117
 Non-responders1111.45 ± 0.55 7.82 ± 0.86 10.36 ± 0.70 0.82 ± 0.12 3183 ± 2231 
Tumor progression
 No progression or platinum-sensitive3510.37 ± 0.380.0565.40 ± 0.520.1609.29 ± 0.430.030*0.89 ± 0.160.6331007.7 ± 300.80.101
 Platinum-resistant1411.57 ± 0.43 6.64 ± 0.80 10.93 ± 0.47 1.14 ± 0.39 3047.4 ± 1839 
  1. * p < 0.05